We have developed comprehensive and proprietary platform tλechnologies which encompass the whole process of siRNA drug development, including siRNA <sequence design and screening, chemical modifications for PD enhanc↓ement and off-target attenuation (eSAFE), liver and extrahepatic deli‌very (STORK), and dual-targeting siRNA. Based on these innovative technologies, we ✘very quickly established a robust pipeline with potentials to become First-in-Class (FIC) and Best-÷in-Class (BIC) siRNA therapeutics for several important therapeutic aλreas, including anti-viral, cardiovascular and metabolic diseases, autoimmune diseases♣, CNS diseases.
We always put the patients’ needs in the highest priority, to innovate best siRNA drugs for th§e health and well-being of human kind.